Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 14, 2023 01:00 ET | Source: Molecular Partners

Molecular Partners to Present Additional Preclinical Data Supporting the Company’s Radio DARPin Therapy Platform at AACR

Targeted radionuclide delivery platform strengthened by new safety and mechanistic dataData includes review of high tumor penetration potential of DARPins and reduced kidney accumulation via DARPin...
April 04, 2023 11:44 ET | Source: Molecular Partners

Molecular Partners Announces Shareholders Approve All Board Proposals at the Annual General Meeting

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., April 04, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of...
March 13, 2023 09:30 ET | Source: Molecular Partners

Molecular Partners Publishes Invitation to Annual General Meeting 2023

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 13, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of...
March 09, 2023 16:00 ET | Source: Molecular Partners

Molecular Partners Reports Corporate Highlights From Q4 2022 and Key Financials for Full Year 2022

Research & Development Highlights: Initiated Phase 1 study of MP0533, a novel tri-specific T-cell engager for the treatment of acute myeloid leukemia (AML) and high risk myelodysplastic syndrome...
March 02, 2023 16:00 ET | Source: Molecular Partners

Molecular Partners to Hold Conference Call to Discuss Fourth Quarter and Full Year 2022 Results and Present at the 43rd Annual Cowen Health Care Conference

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of...
February 28, 2023 01:15 ET | Source: Molecular Partners

Molecular Partners Presents New Preclinical Data Supporting Its Radio DARPin Therapy Platform

Proprietary Radio DARPin Therapy Platform designed to deliver high amount of radioactivity to the tumor while maintaining low accumulation in other tissues Data reveal engineering approach to...
February 10, 2023 01:00 ET | Source: Molecular Partners

Molecular Partners to Present at SVB Leerink Global Healthcare Conference

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 10, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of...
January 16, 2023 01:00 ET | Source: Molecular Partners

Molecular Partners Initiates Clinical Study of Trispecific Candidate MP0533 for the Treatment of Acute Myeloid Leukemia

Unique avidity driven mechanism engages CD3 on T cells when binding either two or three tumor-associated antigens to enhance selectivity for AML cellsPreclinical data demonstrated that MP0533 can...
January 08, 2023 15:00 ET | Source: Molecular Partners

Molecular Partners Provides Updates at 41st Annual JPM Healthcare Conference

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Jan. 08, 2023 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR : Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage...
December 30, 2022 01:00 ET | Source: Molecular Partners

Molecular Partners to Present at 41st Annual JP Morgan Healthcare Conference and Swiss Investor Conferences

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 30, 2022 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of...